Skye Bioscience, Inc.

For the period ended Dec 31, 2024. Filed Mar 20, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 20, 2025

SKYE$0.69-30.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Skye Bioscience, Inc.a Nevada corporation
March 20, 2025	By:	/s/ Punit Dhillon
		Punit Dhillon
	Its:	Director, Chief Executive Officer
		(Principal Executive Officer)
March 20, 2025	By:	/s/ Kaitlyn Arsenault
		Kaitlyn Arsenault
	Its:	Chief Financial Officer
		(Principal Financial and Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By:	/s/ Punit Dhillon	March 20, 2025
	Punit Dhillon
Its:	Director, Chief Executive Officer
	(Principal Executive Officer)
By:	/s/ Kaitlyn Arsenault	March 20, 2025
	Kaitlyn Arsenault
Its:	Chief Financial Officer
	(Principal Financial and Accounting Officer)
By:	/s/ Paul Grayson	March 20, 2025
	Paul Grayson
Its:	Director, Chairman
By:	/s/ Deborah Charych	March 20, 2025
	Deborah Charych
Its:	Director
By:	/s/ Andrew J. Schwab	March 20, 2025
	Andrew J. Schwab
Its:	Director
By:	/s/ Karen Smith	March 20, 2025
	Karen Smith
Its:	Director
By:	/s/ Annalisa Jenkins	March 20, 2025
	Annalisa Jenkins
Its:	Director

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.